Influence of lipophilicity and stereochemistry at the C7 position on the cardioprotective and antioxidant effect of ginkgolides during rat heart ischemia and reperfusion

Drug Development Research

Volumn 64, Issue 3, 2005, Pages 157-171

  Billottet, Ludovic ^a   Martel, Sophie ^b   Culcasi, Marcel ^a,c   Drieu, Katy ^d   Carrupt, Pierre Alain ^b   Pietri, Sylvia ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c SARL OXYLAB   (France)

^d IPSEN   (France)

Author keywords

Anti PAF effect; Ginkgolides; Ischemia reperfusion; Lipophilicity; Stereochemistry

Indexed keywords

7 ALPHA O (4 METHYLPHENYL)GINKGOLIDE C; 7 O (METHYLPHENYL)GINKGOLIDE C; 7 O TRIFLUOROMETHANESULFONYLGINKGOLIDE C; ADENOSINE TRIPHOSPHATE; CREATINE KINASE; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE DERIVATIVE; LACTATE DEHYDROGENASE; MALONALDEHYDE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; GINKGO BILOBA; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEMODYNAMICS; IC 50; LIPID PEROXIDATION; LIPOPHILICITY; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL ANALYSIS; STEREOCHEMISTRY; THROMBOCYTE AGGREGATION INHIBITION;

EID: 21844444585     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10424     Document Type: Article

References (68)

1. Alloatti G, Montrucchio G, Emanuelli G, Camussi G. 1992. Platelet-activating factor induced platelet/neutrophil co-operation during myocardial reperfusion. J Mol Cell Cardiol 24:163-171.
2. Alloatti G, Montrucchio G, Camussi G. 1994. Role of platelet-activating factor (PAF) in oxygen-radical-induced cardiac dysfunction. J Pharmacol Exp Ther 269:766-771.
3. Ambrosio G, Flaherty JT, Duilio C, Tritto I, Santoro G, Elia PP, Condorelli M, Chiariello M. 1991. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest 87:2056-2066.
4. Amri H, Ogwuegbu SO, Boujrad N, Drieu K, Papadopoulos V. 1996. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract (EGb 761) and isolated ginkgolides. Endocrinology 137:5707-5718.
5. Amri H, Drieu K, Papadopoulos V, 2003. Transcriptional suppression of the adrenal cortical peripheral-type benzodiazepine receptor gene and inhibition of steroid synthesis by ginkgolide B. Biochem Pharmacol 65:717-729.
6. Berti F, Magni F, Rossoni G, Puglisi L, Beretta A, Berti M, Tondo C, Villa L. 1989. The ginkgolide BN 52021 prevents myocardial contracture and arrhythmia in ischemic rabbit heart. In: Braquet P, editor. Ginkgolides- chemistry, biology, pharmacology and clinical perspectives. Vol 2. JR Prous Science Publisher, S.A. p 369-380.
7. Berti F, Magni F, Rossoni G, De Angelis L, Galli G. 1990. Production and biologic interactions of prostacyclin and platelet activating factor in acute myocardial ischemia in the perfused rabbit heart. J Cardiovasc Pharmacol 16:727-735.
8. Biber A, Koch E. 1999. Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med 65: 192-193.
9. Bouaziz N, Redon M, Quéré L, Remacle J, Michiels C. 2002. Mitochondrial respiratory chain as a new target for anti-ischemic molecules. Eur J Pharmacol 441:35-45.
10. Braquet P. 1987. The ginkgolides: potent platelet-activating factor antagonists isolated from Ginkgo biloba L.: chemistry, pharmacology and clinical applications. Drugs Future 12:643-699.
11. Braquet P, Esanu A, Buisine E, Hosford D, Broquet C, Koltai M. 1991. Recent progress in ginkgolide research. Med Res Rev 11:295-355.
12. Braquet PG, Spinnewyn B, Braquet M, Bourgain RH. Taylor JE, Etienne A, Drieu K. 1985. BN 52021 and related compounds: a new series of highly specific PAF-acether antagonists isolated from Ginkgo biloba L. Blood Vessels 16:558-.572.
13. Cazaux J-B, Dafniet M, Rebollo J, Teng BP 1995. Two-step process for the preparation of ginkgolide B from ginkgolide C by intermediate sulfonate formation followed by borohydride reduction. Eur Pat Appl EP 680968 (Chem Abstr 1995, 124:176580).
14. Chen J, Hu L, Jiang H, Gu J, Zhu W, Chen Z, Chen K, Ji R. 1998. A 3D-QSAR study on ginkgolides and their analogues with comparative molecular field analysis. Bioorg Med Chem 8:1291-1296.
15. Cheung F, Siow YL, O K. 2001. Inhibition by ginkgolides and bilobalide of the production of nitric oxide in macrophages (THP-1) but not in endothelial cells (HUVEC). Biochem Pharmacol 61:503-510.
16. Corey EJ, Gavai AV. 1989. Simple analogs of ginkgolide B which are highly active antagonists of platelet activating factor. Tetrahedron Lett 30:6959-6962.
17. Corey EJ, Srinivas Rao K. 1991. Enantioselective total synthesis of ginkgolide derivatives lacking the tert-butyl group, an essential structural subunit for antagonism of platelet activating factor. Tetrahedron Lett 32:4623-4626.
18. Corey EJ, Rao KS, Ghosh AK. 1992. Intramolecular and intermolecular hydroxyl reactivity differences in ginkgolides A, B and C and their chemical applications. Tetrahedron Lett 33:6955-6958.
19. DeFeudis FV. 1998. Ginkgo biloba extract (EGb 761). From chemistry to the clinic. Wiesbaden: Ullstein Medical.
20. Fourtillan JB, Brisson AM, Girault J, Ingrand I, Decourt J-P, Drieu K, Jouenne P, Biber A. 1995. Propriétés pharmacocinétiqiues du bilobalide et des ginkgolides A et B chez le sujet sain après administrations intraveineuses et orales d'extrait de Ginkgo biloba (EGb 761). Thérapie 50:137-144.
21. Furukawa S. 1932. Untersuchung über die bestandteile von "Ginkgo biloba L". Chem Zentralbl II:3901-3902.
22. Harper IS, Merwe EVD, Owen P, Opie LH. 1990. Ultrastructural correlates of ischaemic contracture during global subtotal ischaemia in the rat heart. J Exp Path 71:257-268.
23. Hearse DJ, Garlick PB, Humphrey SM. 1977. Ischemic contracture of the myocardium: mechanisms and prevention. Am J Cardiol 39:986-993.
24. Hu L, Chen Z, Cheng X, Xie Y. 1999. Chemistry of ginkgolides: structure-activity relationship as PAF antagonists. Pure Applied Chem 71:1153-1156.
25. Hu L, Chen Z, Xie Y, Jiang Y, Zhen H. 2000. Alkyl and alkoxycarbonyl derivatives of ginkgolide B: synthesis and biological evaluation of PAF inhibitory activity. Bioorg Med Chem 8:1515-1521.
26. Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J. 1995. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem Pharmacol 50:991-999.
27. Janssens D, Remacle J. Drieu K, Michiels C. 1999. Protection of mitochondrial respiration activity by bilobalide. Biochem Pharmacol 58:109-119.
28. Jaracz S, Stromgaard K, Nakanishi K. 2002. Ginkgolides: selective acetylations, translactonization and biological evaluation. J Org Chem 67:4623-1626.
29. Katoh S, Toyama J, Kodama I, Koike A, Abe T. 1993. Pole of platelet-activating factor in ischemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc Res 27:1430-1434,
30. Koltai M, Tosaki A, Hosford D, Braquet P. 1989. Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. Eur J Pharmacol 164:293-302.
31. i elevation and ATP depletìon. Am J Physiol 258:H9-H16.
32. Krieglstein J, Ausmeier F, El-Abhar H, Lippert K, Welsch M, Rupalla K, Henrich-Noack P. 1995. Neuroprotective effects of Ginkgo biloba constituents. Eur J Pharm Sci 3:39-48.
33. Lagente V, Simonetti MPB, Fortes ZB, Braquet P. 1989. Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairment in rats. Pharmacol Res 21:577-585.
34. Lang Q, Wai CM. 1999. An extraction method for determination of ginkgolides and bilobalide in Ginkgo leaf extracts. Anal Chem 71:2929-2933.
35. Lenoir M, Pedruzzi E, Rais S, Drieu K, Perianin A. 2002. Sensitization of human neutrophil defense activities through activation of platelet-activating factor receptors by ginkgolide B, a bioactive component of the Ginkgo biloba extract EGb 761. Biochem Pharmacol 63:1241-1249.
36. Liebgott T, Miollan M, Berchadsky Y, Drieu K, Culcasi M, Pietri S. 2000. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol 95:368-377.
37. Liu X. 2003. New approaches to measure lipophilicity: applications and interpretation. PhD Thesis. University of Lausanne, Switzerland.
38. oct: a tool for lipophilicity determination in drug discovery. J Med Chem 43:2922-2928.
39. Lowry OH, Rosebrough NJ, Farr A, Randall RJ. 1951. Protein measurement with the folinphenol reagent. J Biol Chem 193: 265-275.
40. Maruyama M, Terahara A, Itagaki Y, Nakanishi K. 1967. The ginkgolides. I. Isolation and characterization of the various groups. Tetrahedron Lett 4:299-302.
41. Montrucchio G, Alloatti G, Tetta C, De Luca R, Saunders RN, Emanueli G, Camussi G. 1989. Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol 256:H1236-H1242.
42. Montrucchio G, Alloatti G, Camussi G. 2000. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 80:1669-1699.
43. Neely JR, Grotyohann LW. 1984. Role of glycolytic products in damage to ischemic myocardium. Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ Res 55:816-824.
44. Okabe K, Yamada K, Yamamura S, Takada S. 1967. Ginkgolides. J Chem Soc C 2001-2006.
45. Okhawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358.
46. Pietri S, Maurelli E, Drieu K, Culcasi M. 1997. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 29:733-742.
47. Pietri S, Liebgott T, Finet JP, Culcasi M, Billottet L, Bernard-Henriet C. 2001. Synthesis and biological studies of a new ginkgolide C derivative: evidence that the cardioprotective effect of ginkgolides is unrelated to PAF inhibition. Drug Dev Res 54:191-201.
48. Pietri S, Mercier A, Mathieu C, Caffaratti S, Culcasi M. 2003. Hemodynamic and metabolic effects of the ?-phosphorylated nitroxide 2-diethoxyphosphoryl-2,5,5-trimethylpyrrolidinoxyl during myocardial ischemia and reperfusion. Free Rad Biol Med 34:1167-1177.
49. Rapin JR, Zaibi M, Drieu K. 1998. In vitro and in vivo effects of an extract of Ginkgo biloba (EGb 761), ginkgolide B, and bilobalide on apoptosis in primary cultures of rat hippocampal neurons. Drug Dev Res 45:23-29.
50. Rioufol G, Pietri S, Culcasi M, Loufoua J, Staat P, Pop C, Drieu K, Ovize M. 2003. Ginkgo biloba extract EGb 761 attenuates myocardial stunning in the pig heart. Basic Res Cardiol 98:59-68.
51. Romaschin AD, Wilson GJ, Thomas U, Feitler DA, Tumiati L, Mickle DAG. 1990. Subcellular distribution of peroxidized lipids in myocardial reperfusion injury. Am J Physiol 259:H116-H123.
52. Steenbergen C, Murphy E, Watts JA, London RE. 1990. Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. Circ Res 66:135-146.
53. Stromgaard K, Saito DR, Shindou H, Ishii S, Shimizu T, Nakanishi K. 2002. Ginkgolide derivatives for photolabeling studies: preparation and pharmacological evaluation. J Med Chem 45:4038-4046.
54. Suleiman MS, Halestrap AP, Griffiths EJ. 2001. Mitochondria: a target for myocardial protection. Pharmacol Ther 89:29-46.
55. Takeo S, Kajiwara H, Tanonaka K, Nasa Y, Nakajima Y, Ohya Y, Kaizuka Y. 2000. Cardioprotective effect of a novel cyclohexane dicarboximide derivative, ST-6, against ischemia/reperfusion injury. Drug Dev Res 51:20-28.
56. Tsai R-S, Carrupt P-A, Testa B, El Tayar N, Grunewald GL, Casy AF. 1993. Influence of stereochemical factors on the partition coefficient of diastereomers in a biphasic octan-1-ol/water system. J Chem Res Synopses 8:298-299.
57. van de Waterbeemd H, Kansy M, Wagner B, Fischer H. 1996. Lipophilicity measurement by reversed-phase high performance liquid chromatography (RP-HPLC). In: Pliska V, Testa B, van de Waterbeemd H, editors. Lipophilicity in drug action and toxicology. Weinheim: VCH Publishers, p 73-87.
58. Vanoverschelde J-LJ, Janier MF, Bergman SR. 1994. The relative importance of myocardial energy metabolism compared with ischemic contracture in the determination of ischemic injury in perfused rabbit hearts. Circ Res 74:817-828.
59. Ventura-Clapier R, Vassort G. 1981. Rigor tension during metabolic and ionic rises in resting tension in rat heart. J Mol Cell Cardiol 13:551-561.
60. Ventura-Clapier R, Veksler V. 1994. Myocardial ischemic contracture. Metabolites affect rigor tension development and stiffness. Circ Res 74:920-929.
61. Ventura-Clapier R, Veksler V,7 Hoerter JA. 1994. Myofibrillar creatine kinase and cardiac contraction. Mol Cell Biochem 133/ 134:125-144.
62. Vogensen SB, Stromgaard K, Shindou H, Jaracz S, Suehiro M, Ishii S, Shimizu T, Nakanishi K. 2003. Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem 46:601-608.
63. Wainwright CL, Parratt JR. 1989. Effect of BN 52021 on platelet behavior and arrhythmias during myocardial ischemia and reperfusion. In: Braquet P, editor. Ginkgolides-chemistry, biology pharmacology and clinical perspectives. Vol 2. JR Prous Science Publisher, S.A. p 369-380.
64. Weinges K, Schick H. 1991. Chemie der ginkgolide, IV. Herstellung von ginkgolid B aus ginkgolid C. Liebigs Ann Chem 81-83.
65. Weinges K, Rümmler M, Schick H. 1993. Chemie der ginkgolide, VI. Herstellung von 1,10-dihydroxy und 1,7,10-trihydroxyginkgolid aus 1,3,7,10-tetrahydroxyginkgolid. Liebigs Ann Chem 1023-1027.
66. Yuan G, Kaneko M, Masuda H, Hon RB, Kobayashi A, Yamazaki N. 1992. Decrease in heart mitochondrial creatine kinase activity due to oxygen free radicals. Biochim Biophys Acta 1140:78-84.
67. Zekri O, Boudeville P, Genay P, Perly B, Braquet P, Jouenne P, Burgot JL. 1996. Ionization constants of ginkgolide B in aqueous solution. Anal Chem 68:2598-2604.
68. Zhao HW, Li X-Y. 2002. Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity. Int Immunopharmacol 2: 1551-1556.